A carregar...
Generation, characterization, and maintenance of trastuzumab-resistant HER2+ breast cancer cell lines
Trastuzumab became the therapy of choice for patients with HER2-positive breast cancer in 1998, and it has provided clinical benefit ever since. However, a significant percentage of patients show primary resistance to trastuzumab at diagnosis, and most patients with metastatic disease that initially...
Na minha lista:
| Publicado no: | Am J Cancer Res |
|---|---|
| Main Authors: | , , , , , , , , , , , |
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado em: |
e-Century Publishing Corporation
2016
|
| Assuntos: | |
| Acesso em linha: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5126281/ https://ncbi.nlm.nih.gov/pubmed/27904779 |
| Tags: |
Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!
|